⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AIM News
AIM ImmunoTech Inc.
Form 8-K
sec.gov
AIM
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
globenewswire.com
AIM
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
globenewswire.com
AIM
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness
globenewswire.com
AIM
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
globenewswire.com
AIM
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration
globenewswire.com
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
globenewswire.com
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
globenewswire.com
AIM